U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07489976) titled 'IIT2025-03-YANG-LIFT-HCC' on March 17.
Brief Summary: The investigators are doing this study to learn if a combination of immunotherapy and a liver-directed tumor procedure can safely and effectively shrink or control liver cancer (hepatocellular carcinoma, HCC). The goal is to try to lower the stage of the cancer so that more patients may become eligible for a liver transplant. The investigators will also closely watch for side effects from the study treatments. Section 2 has more details.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Hepato Cellular Carcinoma
Intervention:
DRUG: STRIDE Regimen (Tremelimum...